Please login to the form below

Not currently logged in
Email:
Password:

Former Sanofi SVP to chair Idera

James Geraghty joins the firm with 20 years biotech experience from Genzyme

James Geraghty, IderaIdera Pharmaceuticals has named James Geraghty as the company's new chairman.

Idera specialises in developing toll-like receptors (TLRs) for autoimmune and inflammatory conditions and will benefit from Geraghty's extensive career in the life sciences industry, which includes 20 years ion senior roles at leading biotech Genzyme.

He was later appointed senior VP, North America strategy at Sanofi after the company took over Genzyme in 2011, before leaving earlier this year to become entrepreneur-in-residence at venture capital firm Third Rock Ventures.

“I believe that the addition of Jim and his extensive experience comes at an ideal moment, and we look forward to his guidance and contributions as we advance our programmes toward later stage development,” said Dr Sudhir Agrawal, CEO of Idera.

These programmes involve the company's TLR antagonist drug candidates, which Idera says have shown proof-of-concept in clinical trials and are set for further studies in psoriasis and other conditions.

19th July 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics